Teleflex Incorporated (NYSE:TFX - Free Report) - Equities research analysts at Zacks Research issued their Q3 2025 earnings per share (EPS) estimates for Teleflex in a research note issued on Wednesday, August 13th. Zacks Research analyst Team anticipates that the medical technology company will post earnings of $3.38 per share for the quarter. The consensus estimate for Teleflex's current full-year earnings is $13.98 per share. Zacks Research also issued estimates for Teleflex's Q4 2025 earnings at $4.02 EPS, FY2025 earnings at $14.04 EPS, Q1 2026 earnings at $3.07 EPS, Q2 2026 earnings at $3.74 EPS, Q3 2026 earnings at $4.10 EPS, Q4 2026 earnings at $3.46 EPS, FY2026 earnings at $14.38 EPS, Q1 2027 earnings at $4.03 EPS, Q2 2027 earnings at $3.88 EPS and FY2027 earnings at $16.35 EPS.
Several other equities analysts have also recently issued reports on TFX. Royal Bank Of Canada boosted their price target on Teleflex from $130.00 to $135.00 and gave the company a "sector perform" rating in a research report on Friday, August 1st. Wells Fargo & Company dropped their price target on Teleflex from $137.00 to $131.00 and set an "equal weight" rating on the stock in a research report on Friday, August 1st. Morgan Stanley dropped their target price on Teleflex from $191.00 to $173.00 and set an "overweight" rating on the stock in a research report on Monday, May 5th. Mizuho boosted their target price on Teleflex from $130.00 to $135.00 and gave the stock a "neutral" rating in a research report on Friday, August 1st. Finally, Wall Street Zen upgraded Teleflex from a "hold" rating to a "strong-buy" rating in a research report on Saturday, August 2nd. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating, one has assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, Teleflex has an average rating of "Hold" and a consensus target price of $141.57.
View Our Latest Stock Report on TFX
Teleflex Stock Performance
Shares of TFX stock opened at $121.68 on Friday. The stock has a market capitalization of $5.38 billion, a PE ratio of 28.63, a price-to-earnings-growth ratio of 1.71 and a beta of 1.08. Teleflex has a 52-week low of $108.90 and a 52-week high of $249.90. The stock's 50-day moving average price is $117.97 and its 200 day moving average price is $133.22. The company has a quick ratio of 1.44, a current ratio of 2.41 and a debt-to-equity ratio of 0.42.
Teleflex (NYSE:TFX - Get Free Report) last posted its earnings results on Thursday, July 31st. The medical technology company reported $3.73 EPS for the quarter, topping analysts' consensus estimates of $3.36 by $0.37. The business had revenue of $780.90 million for the quarter, compared to analysts' expectations of $771.53 million. Teleflex had a return on equity of 15.08% and a net margin of 6.31%. The business's revenue was up 4.2% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $3.42 earnings per share.
Institutional Investors Weigh In On Teleflex
Institutional investors and hedge funds have recently bought and sold shares of the stock. Thurston Springer Miller Herd & Titak Inc. raised its holdings in Teleflex by 242.9% in the 2nd quarter. Thurston Springer Miller Herd & Titak Inc. now owns 216 shares of the medical technology company's stock valued at $26,000 after acquiring an additional 153 shares during the last quarter. MassMutual Private Wealth & Trust FSB increased its holdings in Teleflex by 103.1% in the 1st quarter. MassMutual Private Wealth & Trust FSB now owns 197 shares of the medical technology company's stock valued at $27,000 after purchasing an additional 100 shares in the last quarter. Banque Cantonale Vaudoise acquired a new stake in Teleflex in the 1st quarter valued at $27,000. Costello Asset Management INC acquired a new stake in Teleflex in the 1st quarter valued at $28,000. Finally, Brooklyn Investment Group increased its holdings in Teleflex by 258.6% in the 1st quarter. Brooklyn Investment Group now owns 208 shares of the medical technology company's stock valued at $29,000 after purchasing an additional 150 shares in the last quarter. Hedge funds and other institutional investors own 95.62% of the company's stock.
Insider Transactions at Teleflex
In related news, Director Stuart A. Randle bought 1,000 shares of Teleflex stock in a transaction that occurred on Tuesday, August 5th. The shares were purchased at an average price of $115.86 per share, with a total value of $115,860.00. Following the purchase, the director owned 7,547 shares in the company, valued at $874,395.42. This represents a 15.27% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Gretchen R. Haggerty bought 500 shares of Teleflex stock in a transaction that occurred on Wednesday, August 6th. The stock was bought at an average cost of $114.75 per share, for a total transaction of $57,375.00. Following the purchase, the director owned 6,305 shares in the company, valued at $723,498.75. This represents a 8.61% increase in their position. The disclosure for this purchase can be found here. Insiders have bought 5,500 shares of company stock worth $633,590 in the last quarter. Insiders own 1.40% of the company's stock.
Teleflex Announces Dividend
The business also recently announced a quarterly dividend, which will be paid on Monday, September 15th. Investors of record on Friday, August 15th will be paid a $0.34 dividend. The ex-dividend date of this dividend is Friday, August 15th. This represents a $1.36 dividend on an annualized basis and a yield of 1.1%. Teleflex's dividend payout ratio is presently 32.00%.
Teleflex Company Profile
(
Get Free Report)
Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Teleflex, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Teleflex wasn't on the list.
While Teleflex currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access